News Science

Medical Cannabis For More States

Medical cannabis
Cara Wietstock
Written by Cara Wietstock

Israeli cannabis company Tikun Olam, Hebrew for “repair the world”, announced just days ago that their products will be available in more states in the US. This is due to a recent expansion of a licensing agreement with Marimed, Inc., a management company in the US medical cannabis industry.  

“Tikun Olam is delighted to expand our relationship with MariMed,” says Tikun CEO Bernard Sucher.  “MariMed utilizes the “best practices” and standards for cultivation and production and their qualified distribution channels allow us to bring our proven wellness products to more U.S. patients than ever before.”

Tikun Olam has been operating as a commercial venture for more than a decade. With this history, their products have been used in clinical trials in Israel since 2010. In these trials, the medical cannabis pioneers have treated more than 10,000 patients for symptoms associated with Cancer, PTSD, AIDS, epilepsy, Crohn’s Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy. It is through this direct contact with real patients that Tikun Olam has created proprietary cannabis cultivars like the low-THC, high-CBD Avidekel™ and the 1:1 cultivar Midnight™.

“After the great success of our program in Delaware, MariMed is excited to bring Tikun™ to our expanding national network of legal cannabis production and dispensary facilities,” says Robert Fireman, CEO of MariMed Inc.

Tikun Olam currently has similar partnerships in Canada, Australia, Germany, and South Africa. As Fireman mentioned, in 2015 MariMed and Tikun Olam launched a pilot program in Delaware. By March of this year, they had launched in Nevada and by November will have expanded to Washington state. In 2018 flowers of these medicinal strains along with topicals, vape cartridges, edibles, and tinctures will be made available in Rhode Island, Massachusetts, Maryland, and Illinois.

Fireman continued, “Tikun Olam’s empirical data on clinical effectiveness is unsurpassed, and we look forward to educating healthcare professionals and offering Tikun’s products to tens of thousands of new patients nationwide.”

Images are from tikunolamusa.com.

About the author

Cara Wietstock

Cara Wietstock

Cara began working in the retail cannabis industry of San Francisco, CA in 2011 and continued in that sector for years. In 2015 she dedicated herself to writing full-time. Her passion for the written word and deep respect for the healing properties of the plant have brought her to Terpenes and Testing magazine. She now helps keep us on the cutting edge of scientific cannabis discovery as the Editor-in-Chief of the print publication.

Leave a Comment

1 Comment

0
Connecting
Please wait...
Send a message

Sorry, we aren't online at the moment. Leave a message.

Your name
* Email
* Describe your issue
Login now

Need more help? Save time by starting your support request online.

Your name
* Email
* Describe your issue
We're online!
Feedback

Help us help you better! Feel free to leave us any additional feedback.

How do you rate our support?